Baum, Danielle

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

Guttman-Yassky, E., Brunner, P. M., Neumann, A. U., Khattri, S., Pavel, A. B., Malik, K., Singer, G. K., Baum, D., Gilleaudeau, P., Sullivan-Whalen, M., et al. (2018) · Journal of the American Academy of Dermatology

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 343

Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis

Ungar, B., Pavel, A. B., Li, R., Kimmel, G., Nia, J., Hashim, P., Kim, H. J., Chima, M., Vekaria, A. S., Estrada, Y., et al. (2021) · Journal of Allergy and Clinical Immunology

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 119